Low SK, et al. - In this investigation involving 29,981 neuroendocrine tumors (NETs) patients, researchers examined the competing causes of deaths and the risk factors correlated with competing mortality by the standardized mortality ratios and by using the Fine and Gray multivariate regression model. Data reported that 42.5% of the deaths occurring during follow-up were attributed to competing causes (83.9% from noncancer causes and 16.1% from second primary neoplasms). Competing mortality was significantly linked to advanced age, black race, small intestinal and gastric NETs and surgery. Female, pancreatic and recto-anal NETs, distant and regional spread, chemotherapy and radiotherapy have been correlated significantly with reduced competing mortality. Competing mortality plays an increasingly important role over the years and may hinder attempts to enhance NET patients' survival results.